TAIPEI, Taiwan, January 26, 2026－TaiGen Biopharmaceuticals Holdings Ltd. (“TaiGen”) announced today that it has signed an exclusive license agreement with Boryung Biopharma for the commercialization of its novel influenza antiviral, Pixavir marboxil (TG-1000). Under the agreement, Boryung Biopharma receives exclusive rights to develop and market Pixavir marboxil in South Korea, TaiGen will receive an upfront payment, milestone payments, and royalties on net sales. This deal marks another significant milestone in Pixavir’s global expansion, following partnerships in China and India.

Driven by recent outbreaks of potent viral strains, the South Korean influenza market demonstrates robust demand with significant potential for continued expansion. According to national health statistics, the number of confirmed influenza cases in South Korea reached a record high of 3.1 million in 2023. Notably, the patient demographic is skewing younger: data indicates that infants, children, and adolescents aged 0 to 19 account for 63% of total cases, highlighting schools and households as primary environments for transmission.

While traditional treatments like Oseltamivir are available, they require a five-day dosing regimen, which often leads to poor adherence, particularly among children and adolescents. Consequently, the convenience of single-dose therapies has become the benchmark for premium treatments in this market. Pixavir marboxil, an innovative cap-dependent endonuclease inhibitor, effectively suppresses viral replication with just a single dose. This advantage not only significantly improves treatment convenience but also resolves dosing challenges for patients, positioning Pixavir to rapidly become the preferred choice for physicians and families in this growing market.

“South Korea is a benchmark pharmaceutical market in Asia, and we are delighted to partner with Boryung Biopharma,” said Kuo-Lung Huang, Chairman of TaiGen. “With their deep distribution network and marketing capabilities in the respiratory and infectious disease sectors, Boryung Biopharma is the ideal partner to bring Pixavir marboxil to South Korean patients. This agreement not only validates Pixavir’s clinical value but serves as a crucial piece in TaiGen’s global commercialization strategy.”

“Pixavir marboxil is an innovative antiviral therapy that has demonstrated strong clinical value and exceptional convenience through its single-dose regimen. We are delighted to partner with TaiGen to bring this important treatment option to patients in South Korea,” said Hong-Du Jang, Representative Executive Director of Boryung Biopharma. “Leveraging our extensive experience in the respiratory and infectious disease areas, as well as our robust commercial capabilities, Boryung Biopharma is committed to ensuring the successful introduction of Pixavir marboxil to the Korean market.”

The alliance with Boryung Biopharma represents another concrete execution of Pixavir marboxil’s global expansion strategy, following successful licensing in China and India. TaiGen remains committed to advancing the commercialization of Pixavir marboxil in additional international markets, aiming to maximize the commercial value of this innovative asset and fully demonstrate the innovative value of Taiwan's biotech R&D.

About Boryung Biopharma Co. Ltd.
Established in 1991 and headquartered in Seoul, Boryung Biopharma is a fully integrated pharmaceutical company specializing in pediatrics and obstetrics-gynecology. The company operates a KGMP-certified vaccine manufacturing facility in Jincheon, ensuring high production standards. Its reputation is built on a robust vaccine portfolio that effectively covers Influenza, Japanese Encephalitis, Hepatitis, and other infectious diseases. Through deep-rooted partnerships with medical institutions, Boryung Biopharma remains committed to R&D and public well-being.

About TaiGen Biotechnology Co. Ltd.
Founded in 2001 and listed on the Taiwan OTC Market in 2014, TaiGen Biotechnology is a fully integrated pharmaceutical company specializing in innovative small-molecule drugs, particularly anti-infectives. The company has strong capabilities in drug development, regulatory strategy, multi-country clinical trials, and international licensing. Its flagship antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia. Pixavir marboxil, its influenza antiviral, has been licensed in China and India, and its NDA submission in China is currently under regulatory review.